Jukka Westermarck
MD, PhD
jukka.westermarck@utu.fi +358 29 450 2880 +358 40 742 3007 Tykistökatu 6 Turku Office: 4124 (B-stairs, 4th floor) ORCID identifier: https://orcid.org/0000-0001-7478-3018(external) |
Role and regulation of phosphatases, particularly tumor suppressor protein phosphatase 2A (PP2A) in human cancers
Jukka Westermarck is a Professor of Cancer Biology, and Research Director, in the Turku Bioscience Centre at University of Turku.
Westermarck earned his medical degree from University of Turku in 1996. Two years later he obtained his PhD degree in Department of Medical Biochemistry and Department of Dermatology at the same University. He was working as a postdoctoral fellow in the laboratory of Dirk Bohmann during 1999-2001 in the European Molecular Biology Laboratory in Heidelberg, Germany. After being appointed as Academy Fellow by the Academy of Finland, he established his own research group at Turku Centre for Biotechnology in 2002. In 2006-2009 he was appointed as a group leader in the Institute of Medical Technology at University of Tampere, and after that he returned back to Turku due to his appointment as a tenure Research Director of Turku Centre for Biotechnology, and as a Professor of Cancer Biology at the Faculty of Medicine. In 2012, he worked as a visiting Professor at Dana-Farber Cancer Institute, Boston.
Professor Westermarck received young researcher prize from Finnish Medical Association Duodecim 2007, and Anders Jahre young investigator prize 2009 from University of Oslo, Norway. In 2017, he became an elected member of the Finnish Academy of Science and Letters.
Prof. Westermarck´s research focuses on role and regulation of phosphatases, particularly tumor suppressor protein phosphatase 2A (PP2A) in human cancers. Based on this work his group has identified several novel signaling principles how PP2A regulates cancer progression, as well as potential novel cancer therapy targets and diagnostic biomarkers.
- UBR5 Is Coamplified with MYC in Breast Tumors and Encodes an Ubiquitin Ligase That Limits MYC-Dependent Apoptosis (2020)
- Cancer Research
(A1 Refereed original research article in a scientific journal) - Arpp19 Promotes Myc and Cip2a Expression and Associates with Patient Relapse in Acute Myeloid Leukemia (2019)
- Cancers
(A1 Refereed original research article in a scientific journal) - CIP2A-promoted astrogliosis induces AD-like synaptic degeneration and cognitive deficits (2019)
- Neurobiology of Aging
(A1 Refereed original research article in a scientific journal) - Combined inhibition of tumor suppressors PTEN and PP2A drives anoikis resistance and is associated with therapy relapse in prostate cancer (2019)
- Cancer Research
(Other publication) - Genistein Decreases APP/tau Phosphorylation and Ameliorates A beta Over-production Through Inhibiting CIP2A (2019)
- Current Alzheimer Research
(A1 Refereed original research article in a scientific journal) - Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide (2019)
- International Journal of Cancer
(A1 Refereed original research article in a scientific journal) - Tutkimus edellä (2019)
- Solubiologi
(D1 Article in a professional journal) - CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer's Disease (2018)
- Cell Reports
(A1 Refereed original research article in a scientific journal) - Enhanced expression of MycN/CIP2A drives neural crest toward a neural stem cell-like fate: Implications for priming of neuroblastoma (2018)
- Proceedings of the National Academy of Sciences of the United States of America
(A1 Refereed original research article in a scientific journal) - Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer (2018)
- International Journal of Biochemistry and Cell Biology
(A2 Refereed review article in a scientific journal ) - Phosphatases catching up with the level of knowledge: Finally druggable? (2018)
- International Journal of Biochemistry and Cell Biology
(B1 Non-refereed article in a scientific journal) - PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells (2018)
- Science Translational Medicine
(A1 Refereed original research article in a scientific journal) - Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer (2018)
- Cancer Medicine
(A1 Refereed original research article in a scientific journal) - Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back (2018)
- FEBS Journal
(B1 Non-refereed article in a scientific journal) - Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56 (2017)
- EMBO Reports
(A1 Refereed original research article in a scientific journal) - PP2A Inactivation Mediated by PPP2R4 Haploinsufficiency Promotes Cancer Development (2017)
- Cancer Research
(A1 Refereed original research article in a scientific journal) - PWP1 Mediates Nutrient-Dependent Growth Control through Nucleolar Regulation of Ribosomal Gene Expression (2017)
- Developmental Cell
(A1 Refereed original research article in a scientific journal) - CIP2A Promotes T-Cell Activation and Immune Response to Listeria monocytogenes Infection (2016)
- PLoS ONE
(A1 Refereed original research article in a scientific journal) - Copy number increase of oncoprotein CIP2A is associated with poor patient survival in human head and neck squamous cell carcinoma (2016)
- Journal of Oral Pathology and Medicine
(A1 Refereed original research article in a scientific journal) - MYC is not detected in highly proliferating normal spermatogonia but is coupled with CIP2A in testicular cancers (2016)
- Matters
(A1 Refereed original research article in a scientific journal)